$XTALPI(02228.HK) YAOZU Technology, a global leading "AI+organ-on-a-chip" enabled new drug R&D platform company incubated by Jingtai Technology (2228.HK), announced the completion of nearly RMB 200 million in A+ round financing. This round of financing was jointly participated by Guofang Venture Capital, Qingsong Capital, GF Xinde, Oriental Fortune Capital, and Yunbo Capital, with existing shareholder Yayi Capital continuing to increase its investment. This is another major financing event following the completion of over RMB 200 million in Series A financing led by China Life Equity Investment and with continued investment from existing shareholders like Jingtai Technology earlier this year. So far, YAOZU Technology has cumulatively completed nearly RMB 400 million in Series A financing, further consolidating its leading position in the AI for Biology track based on artificial intelligence and organ-on-a-chip technology.